INO - Inovio Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.9000
+0.0200 (+0.69%)
As of 10:47AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.8800
Open2.8600
Bid2.9100 x 2200
Ask2.9200 x 1400
Day's Range2.8400 - 2.9450
52 Week Range2.1500 - 6.3000
Volume141,201
Avg. Volume1,071,888
Market Cap284.298M
Beta (3Y Monthly)2.56
PE Ratio (TTM)N/A
EPS (TTM)-0.9970
Earnings DateMay 8, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.75
Trade prices are not sourced from all markets
  • Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs
    Zacks2 days ago

    Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs

    Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.

  • Why Inovio Pharmaceuticals Stock Is Plunging Today
    Motley Fool2 days ago

    Why Inovio Pharmaceuticals Stock Is Plunging Today

    Shareholders are none too pleased with Inovio's cost-cutting initiative. Here's why.

  • Inovio narrows focus, eliminates 80 jobs
    American City Business Journals2 days ago

    Inovio narrows focus, eliminates 80 jobs

    The Montgomery County biotech company says it wants to focus on the commercial development of its late-stage drug candidates targeting the human papillomavirus.

  • PR Newswire3 days ago

    Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates

    Company Cuts Selected Early-Stage R&D Programs, Burn-Rate by 25%, and Staff by 28% Management to Host Conference Call on July 17 at 8:00 AM EDT PLYMOUTH MEETING, Pa. , July 16, 2019 /PRNewswire/ -- Inovio ...

  • Should You Worry About Inovio Pharmaceuticals, Inc.'s (NASDAQ:INO) CEO Salary Level?
    Simply Wall St.3 days ago

    Should You Worry About Inovio Pharmaceuticals, Inc.'s (NASDAQ:INO) CEO Salary Level?

    In 2009 J. Kim was appointed CEO of Inovio Pharmaceuticals, Inc. (NASDAQ:INO). This analysis aims first to contrast...

  • PR Newswire9 days ago

    Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology

    PLYMOUTH MEETING, Pa., July 10, 2019 /PRNewswire/ -- Geneos Therapeutics, a clinical-stage biotech company, a spin-out of Inovio Pharmaceuticals (INO), announced today that the first cancer patient was dosed using the company's GT-EPIC Neoantigen-Targeting Personalized Vaccine Technology. In this first-in-human treatment – part of a clinical collaboration between Geneos and Washington University School of Medicine in St. Louis – a patient with Anaplastic Astrocytoma, a form of advanced brain cancer, is being treated on a Compassionate Use basis with the patient's own tumor-derived neoantigen vaccine.

  • Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100
    Zacks10 days ago

    Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100

    Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.

  • PR Newswire11 days ago

    Inovio Completes Enrollment of VGX-3100 Phase 2 Trial for the Treatment of HPV-Related Vulvar Dysplasia (VIN)

    PLYMOUTH MEETING, Pa., July 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN). VGX-3100 is an immunotherapy that targets human papillomavirus (HPV) 16 and 18 and is being studied for the treatment of HPV-related precancerous lesions and the HPV infection that causes these lesions. Inovio is already evaluating VGX-3100 in two Phase 3 registration trials (REVEAL 1 and REVEAL 2) to treat cervical dysplasia caused by HPV.

  • Inovio Up on Enrollment Closure in Cervical Dysplasia Study
    Zacks22 days ago

    Inovio Up on Enrollment Closure in Cervical Dysplasia Study

    Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.

  • PR Newswire23 days ago

    Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer

    PLYMOUTH MEETING, Pennsylvania, June 26, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) today announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial ("REVEAL 1") of VGX-3100, a novel DNA-based immunotherapy being tested to treat cervical dysplasia caused by human papillomavirus (HPV). Left untreated, cervical dysplasia can progress to cervical cancer. If approved, VGX-3100 would be the first immunotherapy and non-surgical alternative for women with late-stage cervical dysplasia.

  • Inovio Inks $35M Chinese Drug License Deal (INO)
    Investopedia24 days ago

    Inovio Inks $35M Chinese Drug License Deal (INO)

    Inovio secured a $35 million licensing deal, along with a separate equity investment of $35 million.

  • Inovio Pharmaceuticals, Inc. (NASDAQ:INO): Time For A Financial Health Check
    Simply Wall St.last month

    Inovio Pharmaceuticals, Inc. (NASDAQ:INO): Time For A Financial Health Check

    Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is a small-cap stock with a market capitalization of US$240m. While...

  • PR Newswirelast month

    Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device

    PLYMOUTH MEETING, Pennsylvania, June 10, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of Inovio's new commercial intradermal delivery device. DTRA's Medical CBRN Defense Consortium will provide $8.14 million to support Inovio in developing a small, portable, battery-powered intradermal device branded as CELLECTRA® 3PSP to be used in the administration of Inovio's vaccines and therapies which include DTRA developed products.

  • Inovio (INO) Down 36.7% Since Last Earnings Report: Can It Rebound?
    Zackslast month

    Inovio (INO) Down 36.7% Since Last Earnings Report: Can It Rebound?

    Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • State picks next president of Georgia Tech
    American City Business Journalslast month

    State picks next president of Georgia Tech

    The leader of George Mason University is set to become the next president of Georgia Tech. The Board of Regents of the University System of Georgia on Thursday named Ángel Cabrera as the sole finalist for the Georgia Tech presidency. Cabrera is currently president of George Mason University, a renowned research institution and the largest public university in Virginia.

  • GuruFocus.comlast month

    Inovio Pharmaceuticals Inc (INO) CEO Jong Joseph Kim Sold $5 million of Shares

    CEO of Inovio Pharmaceuticals Inc (NASDAQ:INO) Jong Joseph Kim sold 2,129,553 shares of INO on 06/03/2019 at an average price of $2.36 a share.

  • Why Inovio Pharmaceuticals Stock Is Sinking Today
    Motley Fool2 months ago

    Why Inovio Pharmaceuticals Stock Is Sinking Today

    The small biotech continued to feel the impact of a decision by its big partner.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 28) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Arrowhead ...

  • After Hours: DowDuPont Spinoff Leaping to the S&P 500, Inovio's Partner Problems
    Motley Fool2 months ago

    After Hours: DowDuPont Spinoff Leaping to the S&P 500, Inovio's Partner Problems

    How to get a nonexistent company on a major stock index, plus a biotech breakup.

  • MarketWatch2 months ago

    Inovio Pharma stock slips as AstraZeneca unit scales back agreement

    Inovio Pharmaceuticals Inc. shares fell in the extended session Tuesday after the drug developer said that one of its partners is scaling back on a research collaboration. Inovio shares fell 6.7% after hours, following a 3.7% decline to close at $3.14. In a filing with the Securities and Exchange Commission, Inovio said AstraZeneca PLC subsidiary MedImmune is discontinuing a research agreement with the company with the exception of a drug candidate known as "MEDI0457." The companies will continue evaluating the drug for use in cancers associated with human papillomavirus, or HPV, and Inovio will be eligible for milestone payments should the drug receive market approval.

  • CNBC2 months ago

    Stocks making the biggest moves after hours: Workday, Inovio and more

    Shares of Workday W seesawed in extended trading on Tuesday — jumping as much as 2% before falling more than 1% — after the software company reported better-than-expected first-quarter earnings. Inovio Pharmaceuticals INO stock plummeted as much as 11% after news broke that Astrazeneca, a pharmaceutical company, will discontinue its research collaborations with the biotech company. Refinitiv consensus estimates had projected earnings of 49 cents per share and net sales of $479.5 million.

  • PR Newswire2 months ago

    Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial

    PLYMOUTH MEETING, Pa. and OSLO, Norway, May 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO), together with CEPI, today announced it has dosed subjects in a Phase 1, first-in-human clinical trial to evaluate INO-4500, its DNA candidate vaccine to prevent infection from the Lassa virus. Inovio plans to enroll approximately 60 volunteers in this placebo controlled, blinded, dose escalation study evaluating INO-4500 for safety, tolerability and immune responses. This Inovio trial represents the first Lassa candidate vaccine to enter the clinic.